OpGen bags up to $17M in VC deal

OpGen has struck a deal with investors to haul in as much as $17 million in a Series C round of financing, providing the company with growth capital to bolster sales of its genomic research tools and analysis software products, the company said this morning.

The Gaithersburg, MD-based company--whose whole genome mapping technology is intended to provide a more complete and accurate view of the genome than sequencing alone--tapped new investors Harris & Harris Group and Cross Creek Capital for the round, which also included repeat backers Highland Capital Partners, Versant Ventures, jVen Capital and CHL Medical Partners. As part of the deal, Harris & Harris's Misti Ushio has joined OpGen's board of directors.

OpGen, founded in 2001, has seen more than 100 customers use its whole genome mapping technology or services, CEO Doug White told FierceBiotech in an email. Unlike Illumina's ($ILMN) whole genome sequencers, which identify the building blocks of cells in DNA, OpGen's genome maps enable speedy and relatively low cost sequence assembly. With the maps, researchers are able to hunt down structural variations in genomes and chromosomes, a tricky task using sequencing data alone, White said. 

"Our customers are using the technology for sequence assembly and finishing as well as comparative genomics analysis," White said. "We have customers in public health and food safety market, biodefense, genomics research and sequencing centers."

According to its press release, the company's customer base includes BGI, the world's largest sequencing operation, as well as Wellcome Trust Sanger Institute, the Genome Institute at Washington University and the University of Maryland Institute for Genome Sciences.

- here's the press release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.